MAP Pharmaceuticals Inc. and Allergan Inc. will collaborate on marketing MAP's Levadex, a self-administered, orally inhaled therapy for acute migraine in adults. MAP, of Mountain View, Calif., will get $60 million up-front and as much as $97 million if it meets milestones. Read More
LONDON – Antisoma plc has taken a double hit with the failure of its only two clinical programs, as the lead product AS1413 failed in a pivotal Phase III trial in secondary acute myeloid leukemia (AML) and a Phase IIb trial of AS1411 in AML was halted after an interim analysis. Read More
Alexion Pharmaceuticals Inc. acquired Taligen Therapeutics Inc. for $111 million up front with additional contingent payments based on clinical and regulatory milestones. Alexion ended 2010 with $297 million in the bank, so the Taligen acquisition was an affordable move allowing it to neutralize a future competitor and diversify its pipeline. Read More
Shares of NPS Pharmaceuticals Inc. jumped 31.5 percent on positive Phase III data for GLP-2 analogue Gattex (teduglutide) in short bowel syndrome (SBS), and the Bedminster, N.J.-based firm expects to submit a new drug application in the second half of this year. Read More
Depomed Inc. scored a major win with the FDA's approval late Friday of its once-daily tablet formulation of gabapentin, branded Gralise, in postherpetic neuralgia, sending the company's shares soaring more than 34.3 percent Monday. Read More
Sinovac Biotech Ltd., of Beijing, submitted applications to the Chinese SFDA for clinical trials of its pneumococcal polysaccharide vaccines. Preclinical studies showed favorable safety and efficacy profiles in animals. Read More
Savient Pharmaceuticals Inc., of East Brunswick, N.J., said it will offer $125 million aggregate principal amount of convertible senior notes due 2018. The firm also plans to grant underwriters J.P. Morgan Securities LLC and Lazard Capital Markets LLC an option to purchase up to an additional $18.75 million aggregate principal amount of notes to cover overallotments. Read More
Pfizer Inc., of New York, completed its tender offer for Bristol, Tenn.-based King Pharmaceuticals Inc. The firms agreed to an acquisition deal in October that valued King at $14.25 per share, or about $3.6 billion. Read More
